Non-Small-Cell Lung Cancer | Unmet Need | US/EU | 2018



  • What are the treatment drivers and goals for [[indication]]?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for [[indication]]?
  • What are the prevailing areas of unmet need and opportunity in [[indication]]?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European [[physician type, plural]] for a hypothetical new [[indication]] drug?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Login to access report

launch Related Market Assessment Reports